普罗布考对不稳定型心绞痛患者血清明胶酶的影响

摘要

Objective: To investigate effects of probucol on serum levels of gelatinases in patients with unstable angina pectoris (UAP). Methods: A total of 80 UAP patients were continuously enrolled and randomly divided into probucol treatment group (n=40) and routine treatment group (n=40). Routine treatment group was given routine medical treatment with nitrates, aspirin and P-receptor blocker etc; probucol group was given probucol oral additionally based on routine treatment. Serum levels of gelatinases were examined before and one month after treatment. Results: Compared with before treatment, levels of matrix metalloproteinase (MMP) -2 [ (54. 04±6. 54) ng/ml vs. (32. 43±1. 81) ng/ml] and MMP-9 [ (56. 33±7. 25) ng/ml vs. (34 + 1. 45) ng/ml] significantly decreased in probucol treatment group after treatment (P<0. 01 both), and significantly lower than those of routine treatment group [MMP-2: (37.21 + 2.86) ng/ml, MMP-9: (39. 96±1. 75) ng/ml], P<0. 05. Conclusion: Probucol could decrease serum levels of gelatinases in patients with unstable angina pectoris, and possess effect of stabilization of atherosclerotic plaque.%目的:探讨普罗布考对不稳定型心绞痛(UAP)患者血清明胶酶的影响.方法:连续入选UAP患者80例,随机分为普罗布考治疗组(40例)和常规治疗组(40例).常规治疗组采用硝酸酯类、阿司匹林、β受体阻滞剂等常规药物治疗；普罗布考组在常规治疗基础上加用普罗布考口服,观察治疗前及治疗一个月后血清明胶酶水平.结果:与治疗前比较,普罗布考治疗组治疗后基质金属蛋白酶(MMP) -2[(54.04±6.54) ng/ml比(32.43±1.81) ng/ml]、MMP-9[(56.33±7.25) ng/ml比(34±1.45) ng/ml]水平均明显下降(P均＜0.01),且明显低于常规治疗组治疗后[ MMP-2:(37.21±2.86) ng/ml、MMP-9:(39.96±1.75)ng/ml],P＜0.05.结论:普罗布考能促进不稳定型心绞痛患者血清明胶酶水平的下降,起到稳定粥样斑块的作用.